Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,941 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma.
Sussman RT, Rokita JL, Huang K, Raman P, Rathi KS, Martinez D, Bosse KR, Lane M, Hart LS, Bhatti T, Pawel B, Maris JM. Sussman RT, et al. Among authors: lane m. Front Oncol. 2020 Mar 6;10:302. doi: 10.3389/fonc.2020.00302. eCollection 2020. Front Oncol. 2020. PMID: 32211329 Free PMC article.
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov DS, Mackall CL, Maris JM. Bosse KR, et al. Among authors: lane m. Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003. Cancer Cell. 2017. PMID: 28898695 Free PMC article.
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Raman S, Buongervino SN, Lane MV, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Navia CT, Harmon DB, Li Y, Pawel B, Dimitrov DS, Maris JM, Julien JP, Bosse KR. Raman S, et al. Among authors: lane mv. Cell Rep Med. 2021 Jul 21;2(7):100344. doi: 10.1016/j.xcrm.2021.100344. eCollection 2021 Jul 20. Cell Rep Med. 2021. PMID: 34337560 Free PMC article.
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Bosse KR, Giudice AM, Lane MV, McIntyre B, Schürch PM, Pascual-Pasto G, Buongervino SN, Suresh S, Fitzsimmons A, Hyman A, Gemino-Borromeo M, Saggio J, Berko ER, Daniels AA, Stundon J, Friedrichsen M, Liu X, Margolis ML, Li MM, Tierno MB, Oxnard GR, Maris JM, Mossé YP. Bosse KR, et al. Among authors: lane mv. Cancer Discov. 2022 Dec 2;12(12):2800-2819. doi: 10.1158/2159-8290.CD-22-0287. Cancer Discov. 2022. PMID: 36108156 Free PMC article.
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB, Griffin C, Rokita JL, Stern A, Brimley C, Rathi K, Lane MV, Buongervino SN, Smith T, Madsen PJ, Martinez D, Delaidelli A, Sorensen PH, Wechsler-Reya RJ, Karikó K, Storm PB, Barrett DM, Resnick AC, Maris JM, Bosse KR. Foster JB, et al. Among authors: lane mv. J Immunother Cancer. 2022 Sep;10(9):e004450. doi: 10.1136/jitc-2021-004450. J Immunother Cancer. 2022. PMID: 36167467 Free PMC article.
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Modi A, Rokita JL, Patel K, Lane MV, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. Weiner AK, et al. Among authors: lane mv. bioRxiv [Preprint]. 2024 Jan 7:2023.12.06.570390. doi: 10.1101/2023.12.06.570390. bioRxiv. 2024. Update in: Cancer Cell. 2024 Nov 11;42(11):1970-1982.e7. doi: 10.1016/j.ccell.2024.10.003 PMID: 38106022 Free PMC article. Updated. Preprint.
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, Sidoli S, Delaidelli A, Modi A, Rokita JL, Lane MV, Hartnett N, Lopez RD, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. Hamilton AK, et al. Among authors: lane mv. Cancer Cell. 2024 Nov 11;42(11):1970-1982.e7. doi: 10.1016/j.ccell.2024.10.003. Epub 2024 Oct 24. Cancer Cell. 2024. PMID: 39454577 Free article.
1,941 results